Advanced Search
Therapeutic Area Disease
Title Drug Phase
Clinical Trials Listing
Active treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
D0819C00003 A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations (OlympiAD) III Chemotherapy, PARP Inhibitor vinorelbine; capecitabine; eribulin mesylate; olaparib
M12-895 A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer II Chemotherapy, PARP Inhibitor carboplatin; temozolomide; paclitaxel; veliparib
097517 I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2) II Chemotherapy, Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor, PARP Inhibitor trastuzumab; pertuzumab; cyclophosphamide; paclitaxel; doxorubicin; neratinib; veliparib; figitumumab; trebananib; ganitumab; conatumumab; metformin ; ado-trastuzumab emtansine (T-DM1);
12-258 A Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (AC) in Women With Newly Diagnosed Breast Cancer and Germline BrCa Mutations II Chemotherapy cisplatin; cyclophosphamide; doxorubicin
UPCC-04113 A FEASIBILITY AND PHASE II TRIAL OF ACCELERATED PARTIAL BREAST IRRADIATION USING PROTON THERAPY FOR WOMEN WITH STAGE IA-IIA BREAST CANCER II Radiation Therapy, Proton Therapy Not Applicable
UPCC-10114 A Phase 2 Pilot Feasibility Study of Palbociclib in Combination With Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Cancer II Hormonal Therapy, Signal Transduction Inhibitor anastrozole; exemestane; letrozole; palbociclib
UPCC-24213 A Phase Ib/II Clinical Study of BBI608 Administered With Paclitaxel in Adult Patients With Advanced Malignancies I / II Chemotherapy, Signal Transduction Inhibitor paclitaxel;
UPCC 03114 A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS I / II Immunotherapy trastuzumab; HER-2 pulsed DC1 vaccine
UPCC-13514 A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of MK-3475 in Combination With INCB024360 in Subjects With Selected Solid Tumors (Phase 1) Followed by a Randomized, Double-Blind, Placebo-Controlled Study in Subjects With Advanced NSCLC (Phase 2)(INCB 24360-202 / MK-3475-037 / KEYNOTE-037) I / II Immunotherapy (Monoclonal Antibody), Signal Transduction Inhibitor INCB024360; pembrolizumab
818561 Pilot Phase I HER-2 Pulsed DC Vaccine to Prevent Recurrence for Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy I Immunotherapy (Vaccine) Dendritic Cell Vaccine
UPCC 26113 Pilot Phase I HER-2 Pulsed-DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer Post Neoadjuvant Chemotherapy I Immunotherapy (Vaccine) HER-2 pulsed DC1 vaccine
UPCC 40914 RADVAX: A Stratified Phase I Trial of Pembrolizumab With Hypofractionated Radiotherapy in Patients With Advanced and Metastatic Cancers I Radiotherapy pembrolizumab
UPCC 25113 Pilot Phase I HER-2 Pulsed DC Vaccine To Prevent Recurrence For Patients With HER-2 Driven High Risk Invasive Breast Cancer I Immunotherapy (Vaccine) HER-2 pulsed DC1 vaccine
818065 A Pilot & Feasibility Study of the Imaging Potential of EC17 in Subjects Undergoing Surgery Presenting With Triple Negative Breast Cancer I Other
UPCC 13111 Clinical Trial of Autologous cMet Redirected T Cells Administered Intratumorally in Patients With Breast Cancer I Immunotherapy Autologous Tumor Cell Vaccine
UPCC 22913 Phase I Study of TERT DNA and Electroporation With and Without IL-12 DNA for Patients With Breast, Lung, or Pancreatic Cancer at High Risk of Relapse Post Definitive Surgery and Adjuvant Therapy I Immunotherapy Interleukin 12 (IL-12); INO-1400
UPCC-12110 The Effects of Radiation Therapy on the Reconstructed Breast: An Evaluation Using MR Imaging Not Specified Radiotherapy Not Applicable
UPCC-03111 A Study of hTERT/Survivin Multi-Peptide Vaccination With Basiliximab And Prevnar For Patients With Metastatic Breast Cancer Not Specified Immunotherapy (Monoclonal Antibody) basiliximab; prevnar
UPCC 17113 18F-Fluorodeoxyglucose (FDG) Positron Emission Tomography (PET/CT) For The Evaluation Of Response To Therapy In Bone-Dominant Metastatic Breast Cancer Not Specified Imaging Procedure fludeoxyglucose F 18
Active non-treatment trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
AT005074 Long-Term Chamomile Therapy for Generalized Anxiety Disorder (GAD) III Supportive Care Not Applicable
U54-CA 155850 The Women In Steady Exercise Research (WISER) Survivor Trial & Cost of Illness and Cost Effectiveness of Alternative Management Strategies III Other Not Applicable
UPCC-05912 Extended Duration Varenicline for Smoking Among Cancer Patients: A Clinical Trial III Other, Supportive Care varenicline tartrate
UPCC-11111 A Double Blind, Randomized, Placebo-controlled, Parallel Group Study of Sativex® Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Relieving Uncontrolled Persistent Chronic Pain in Patients With Advanced Cancer, Who Experience Inadequate Analgesia During Optimized Chronic Opioid Therapy III Supportive Care GW-1000-02 (Sativex)
UPCC-14111 A Multicenter, Non-comparative, Open-label Extension Study to Assess the Long Term Safety of Sativex® Oromucosal Spray (Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer-related Pain III Other GW-1000-02 (Sativex)
UPCC 30914 Choosing Options for Insomnia in Cancer Effectively (CHOICE): A Comparative Effectiveness Trial of Acupuncture and Cognitive Behavior Therapy 0 Complementary and Alternative Therapy
UPCC-12111 A Phase 0/1, Open-Label, Single Center Study of the Imaging Potential of Indocyanine Green in Subject Undergoing Breast Cancer Surgery 0 Imaging Procedure Indocyanine Green
ROG-SCCI 09-003-2 Enhancing Physical Activity Adherence After Breast Cancer Diagnosis (BEAT Cancer Study II) Not Specified Other Not Applicable
UPCC 01914 Patient-Centered Integration of Acupuncture to Decrease Pain for Cancer Survivors Not Specified Pain Management Not Applicable
COMETI-P2-2012 COMETI Phase 2: Characterization of Circulating Tumor Cells From Subjects With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Not Specified Other Not Applicable
UPCC 08113 A Randomized Study of the Effect of Yoga in Patients With Breast Cancer Receiving Radiation Therapy Not Specified Complementary and Alternative Therapy Not Applicable
UPCC-12807 Assessing Fertility Potential in Female Cancer Survivors Not Specified Imaging Procedure, Blood Test Not Applicable
Active advanced solid tumor trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-03909 Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer II Signal Transduction Inhibitor palbociclib
CO-338-010 A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Breast or Ovarian Cancer, or Other Solid Tumor I / II PARP Inhibitor rucaparib
UPPC-20512 A Phase I Study of Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion I Gene Therapy Adenovirus (Adv)-mediated thymidine kinase ; valacyclovir
UPCC-07913 A Phase 1b, Open-Label, Dose Escalation, Multi-arm Study of MLN4924 Plus Docetaxel, Gemcitabine, or Combination of Carboplatin and Paclitaxel in Patients With Solid Tumors I Chemotherapy, Signal Transduction Inhibitor docetaxel; carboplatin; gemcitabine; paclitaxel;
UPCC-29212 A Phase I/II Open-Label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of GSK525762 in Subjects With NUT Midline Carcinoma (NMC) and Other Cancers I Signal Transduction Inhibitor
08913 A Pilot and Feasibility Study of Intraoperative Imagery of Solid Tumors With Indocyanine Green I Imaging Procedure Indocyanine Green
CLDE225A2112 A Phase Ib, Multi-center, Two Parallel Group, Open-label, Drug-drug Interaction Study to Assess the Effect of LDE225 on the Pharmacokinetics of Bupropion and Warfarin in Patients With Advanced Solid Tumors I Other warfarin; bupropion
UPCC-05314 A Phase 1a/1b Study of the Oral TRK Inhibitor LOXO-101 in Subjects With Adult Solid Tumors I Signal Transduction Inhibitor
CP-MGA271-01 A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer I Immunotherapy (Monoclonal Antibody)
UPCC 01614 A Multicenter Phase 1A/1B Ascending Dose Study of DCC-2701 To Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Patients With Advanced Solid Tumors I Signal Transduction Inhibitor altiratinib
CX-839-001 A Phase 1 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Glutaminase Inhibitor CB-839 in Patients With Advanced and/or Treatment-Refractory Solid Tumors I Signal Transduction Inhibitor
UPCC 19913 A Phase 1, Open-Label, Multicenter, Dose Escalation Study to Assess the Safety and Tolerability of MLN7243, an Inhibitor of Ubiquitin-Activating Enzyme (UAE), in Adult Patients With Advanced Solid Tumors I Signal Transduction Inhibitor
UPCC-23914 A Phase 1, Open-Label, Dose Escalation and Dose Expansion Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Effects of Orally Administered CB-5083 in Patients With Advanced Solid Tumors I Signal Transduction Inhibitor
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable
Active proton therapy trials at Penn's Abramson Cancer Center
Protocol ID Title Phase Modality Drug
UPCC-23309 Retreatment of Recurrent Tumors Using Proton Therapy Not Specified Proton Therapy Not Applicable

Request a call

A clinical trial navigator is available to help you search for clinical trials offered by the Penn Medicine Abramson Cancer Center. This is a confidential free service available Monday-Friday, 9:00am-5:00pm (ET). Requests are processed in the order they are received.



*
*
*
*

Please do not submit another person’s name or email without his or her consent.